Latest Erythropoietin Stories
SAN DIEGO, May 13, 2011 /PRNewswire/ -- ViaCyte, Inc., a preclinical cell therapy company focused on diabetes, today announced the appointment of Anthony ("Tony") Gringeri as Chief Development Officer. Dr. Gringeri brings to ViaCyte more than 20 years of experience successfully leading product development and strategic partnering. His track record includes biologics and gene therapies, which were new technologies to both U.S. and European regulators at the time of their development. Dr....
Intravenous administration of epoetin alfa, a product that stimulates red blood cell production, to patients with heart attack who were undergoing percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), did not provide reduction in the size of the heart muscle involved and was associated with higher rates of adverse cardiovascular events, according to a study in the May 11 issue of JAMA.Patients who survive...
SHIRLEY, N.Y., May 3, 2011 /PRNewswire/ -- American Regent announces that, effective immediately, it has resumed the shipment of Venofer® (iron sucrose injection, USP). Please Note: ALL sizes of Venofer® (50mg/2.5mL, 100mg/5mL and 200mg/10mL Single Dose Vials) are available through your local Wholesaler or Distributor. Drop shipments through your wholesaler are also available. American Regent has filled all open orders for Venofer® and has over 1 million vials in inventory....
New product from Red X Labs designed to increase both testosterone and to increase red blood cell production is now available in the USA without a prescription. Denver, CO (PRWEB) April 23, 2011 Most bodybuilders think of EPO (erythropoietin) as an endurance drug used by long distance runners and cyclists, and it is. However, Red X Labs reveals that this high stamina wonder drug has many applications for bodybuilders as well including muscle growth and fat loss. It's clear why...
NES-ZIONA, Israel, March 14, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it is relocating its corporate office and R&D facility to a new, significantly larger building located a short distance from its current site in the Weizmann Science Park in Nes Ziona, Israel. The move is expected to be completed by April 15. The new headquarters and upgraded R&D facility, which comprise approximately 10,000 square feet of leased space, will allow for...
NES-ZIONA, Israel, Feb. 14, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011. The study is assessing the efficacy of hGH-CTP by measuring IGF-1 levels in growth hormone deficient adults in response...
Evaluating patients for genetic variations impacts adherence to antiviral therapyIn two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus. Full findings of these studies...
NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a...
Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.The results suggest that testing such patients' responsiveness to the drug and keeping blood iron levels a little low might reduce their risk, said Dr. Robert Toto, professor of internal medicine and clinical sciences and a senior author of the study, which appeared in the New...
HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY.PK), a biopharmaceutical company, today announced it has been notified by the Tel Aviv Stock Exchange (TASE) that XTL will be included in the following TASE Indexes; "Yeter" Tel Aviv, "Tel Tech", and "Biomed", effective December 15, 2010. TASE shall conduct a "special trading" in XTL's shares at the end of trading on December 14, 2010. "We are very pleased that our...
